Protocol Ledger

NCT07775924 · Phase II · RECRUITING

A Study to Assess the Efficacy and Safety of GIA632 Across a Range of Doses in Participants With Moderate to Severe Cutaneous Lichen Planus

Interventional Phase II clinical trial protocol NCT07775924 sponsored by Novartis in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-09-29 Enrollment: 259 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07775924
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)259 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07775924
Protocol FieldVerified Registry Value
NCT IdentifierNCT07775924
Consolidated Lead SponsorNovartis
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment259 participants (ESTIMATED)
Registered Start Date2026-09-29
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07775924
Hospital Research SiteLocationSite Profile
First OC DermatologyFountain Valley, CAOpen Hospital Dossier ->
DelRicht ResearchNew Orleans, LAOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Novartis across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI